Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iclepertin in Alzheimer's Disease
NCT02788513Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Aug 2016
- Primary completion
- Sep 2019
- Modality
- Classical Binding Small Molecules
- Countries
- 14
01
Overview
Phase 2, randomised, double-blind trial of iclepertin in Alzheimer's disease (AD) (5 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Alzheimer's Disease Assessment Scale-Cognitive Subscale 11 Item at 12 weeks. Started Aug 2016; status: completed.
02
Drugs
iclepertin
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02788513.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02788513.